血漿分画市場：製品タイプ、分画方法、用途、エンドユーザー別-2025-2030年の世界予測

血漿分画市場は、2024年には367億7,000万米ドルとなり、2025年には402億2,000万米ドル、CAGR 9.65%で成長し、2030年には639億4,000万米ドルに達すると予測されています。

血漿分画は、高度なバイオテクノロジー・プロセスと重要なヘルスケア・ソリューションの交差点に位置しています。強固な科学的革新と救命治療における需要の増加に牽引されるこの市場は、現代医療の本質を体現しています。最近の進歩は、製品の品質、分画法の効率、市場全体の拡大において著しい改善を促しています。血漿タンパク質に由来する治療法の開発における卓越性の追求は、様々な疾患メカニズムの理解を深めるだけでなく、多様な患者集団に恩恵をもたらす応用範囲を拡大しました。

医療の精密さとオーダーメイド治療がますます不可欠になる世界において、血漿分画は基礎技術として浮上しています。継続的な調査、政府の政策支援、戦略的な産業界の協力が、この分野の勢いをさらに加速させています。最先端技術と厳格な品質基準が融合することで、市場は複雑さと範囲の両面で進化を続けています。この情勢のニュアンスを掘り下げていくと、この分野での成功は、科学的誠実さ、業界の先見性、革新への絶え間ないコミットメントという強固な基盤の上に築かれていることが明らかになります。

血漿分画市場の変革

血漿分画のダイナミクスは、研究努力の統合、技術的ブレークスルーの急増、絶え間なく変化する競合環境によって特徴づけられる重大な変化を経験しています。高度に洗練されたバイオプロセス技術の出現は、血漿タンパク質の抽出・精製方法に革命をもたらし、最終的に重要な医薬品の収量と純度を向上させました。こうした進歩は、治療効果と安全性の向上につながり、患者中心のヘルスケアという新たな時代の到来を告げるものです。

加えて、世界の利害関係者間の戦略的提携や合併によって競合の枠組みが変化し、企業は規制上の義務や市場の期待の両方を満たすペースで技術革新を進める必要に迫られています。この変革により、品質保証、プロセスの最適化、次世代技術の迅速な統合に重点が置かれるようになりました。その結果、血漿分画市場のプレーヤーは、厳格な基準を維持するだけでなく、進化する臨床ニーズを予測し、それに適応する必要に迫られています。従来の方法から、より自動化され、拡張可能で持続可能な方法への移行は、業界の変容を象徴しており、将来の進歩が期待されています。

市場の次元にまたがる主要セグメンテーションの洞察

血漿分画市場を詳細に分析すると、複数の重要な要因による包括的なセグメンテーションが明らかになります。製品タイプ別に見ると、市場はアルブミン、凝固因子濃縮物、免疫グロブリン、プロテアーゼ阻害剤を含む膨大な治療物質で構成されています。凝固因子濃縮製剤は、第VIII因子、第XIII因子、フィブリノゲン濃縮製剤、プロトロンビン複合体濃縮製剤などの主要成分に分類することで、さらに細分化されます。免疫グロブリンの領域もまた、静脈注射用免疫グロブリンと皮下注射用免疫グロブリンに区分されており、患者ごとの治療に向けたテーラーメイドのアプローチを反映しています。

市場セグメンテーションはまた、採用されている分画法のレンズを通して複雑にマッピングされています。遠心分離、凍結沈殿、エタノール沈殿、イオン交換クロマトグラフィー、限外ろ過などです。このような方法論的アプローチの多様性は、業界の革新的能力を示すだけでなく、卓越した製品を達成するためのプロセス特有の最適化の重要性を強調しています。これらの製品の用途は、血液学、神経学、腫瘍学、リウマチ学などの重要な医療分野に市場をさらに細分化し、治療パラダイムがますます専門化していることを強調しています。最後に、エンドユーザーの視点では、市場を学術機関、臨床研究機関、病院・診療所などの分野に分け、それぞれ独自の使用パターンと成長の可能性を示すことで、血漿分画市場における今後の戦略を総体的に推進します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 免疫疾患および出血性疾患の治療における血漿由来療法の需要の高まり
    • 収量とバイオセーフティを向上させる分画技術の進歩
    • 血漿収集ネットワークとドナー参加イニシアチブの拡大
  • 抑制要因
    • 高い生産コストと厳しい規制遵守要件
  • 機会
    • ヘルスケア投資の増加により、新興市場における血漿分画の潜在的可能性が高まっている
    • 用途拡大のための組換え代替品およびハイブリッド血漿由来製品の開発
  • 課題
    • サプライチェーンの制約とドナーへの依存が原材料の入手可能性に影響を与える
• 市場セグメンテーション分析
  • 製品タイプ：出血性疾患の管理における凝固因子濃縮物の重要な役割
  • エンドユーザー：調査と教育の推進における学術機関の重要な役割
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 血漿分画市場：製品タイプ別

• アルブミン
• 凝固因子濃縮物
  • 第VIII因子
  • 第XIII因子
  • フィブリノゲン濃縮物
  • プロトロンビン複合体濃縮物
• 免疫グロブリン
  • 静脈内免疫グロブリン
  • 皮下免疫グロブリン
• プロテアーゼ阻害剤

第7章 血漿分画市場分別法別

• 遠心分離
• クライオプレシピテーション
• エタノール沈殿
• イオン交換クロマトグラフィー
• 限外濾過

第8章 血漿分画市場：用途別

• 血液学
• 神経学
• 腫瘍学
• リウマチ学

第9章 血漿分画市場：エンドユーザー別

• 学術機関
• 臨床調査ラボ
• 病院と診療所

第10章 南北アメリカの血漿分画市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の血漿分画市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの血漿分画市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 3M Company
• ADMA Biologics, Inc.
• Bharat Serums and Vaccines Limited
• Bio Products Laboratory Ltd.
• Biotest AG by Grifols, S.A.
• China Biologic Products, Inc.
• CSL Limited
• Emergent BioSolutions Inc.
• GC Biopharma corp.
• HEINKEL Process Technology GmbH
• Hemarus Therapeutics Ltd
• Intas Pharmaceuticals Ltd.
• Kamada Ltd.
• Kedrion S.p.A.
• LFB SA
• Merck KGaA
• Octapharma AG
• PlasmaGen BioSciences Pvt. Ltd.
• Prothya Biosolutions B.V.
• Shanghai Raas Blood Products Co. Ltd.
• SK Plasma Co.,Ltd.
• STERIS plc
• Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

• FIGURE 1. PLASMA FRACTIONATION MARKET MULTI-CURRENCY
• FIGURE 2. PLASMA FRACTIONATION MARKET MULTI-LANGUAGE
• FIGURE 3. PLASMA FRACTIONATION MARKET RESEARCH PROCESS
• FIGURE 4. PLASMA FRACTIONATION MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PLASMA FRACTIONATION MARKET DYNAMICS
• TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR XIII, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRYOPRECIPITATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ETHANOL PRECIPITATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ION-EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. POLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. QATAR PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY METHOD OF FRACTIONATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 286. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2024

The Plasma Fractionation Market was valued at USD 36.77 billion in 2024 and is projected to grow to USD 40.22 billion in 2025, with a CAGR of 9.65%, reaching USD 63.94 billion by 2030.

Plasma fractionation stands at the crossroads of advanced biotechnological processes and critical healthcare solutions. This market, driven by robust scientific innovation and increasing demand in life-saving therapies, embodies the essence of modern medicine. Recent advancements have fostered significant improvements in product quality, efficiency of fractionation methods, and overall market expansion. The pursuit of excellence in developing treatments derived from plasma proteins has not only deepened our understanding of various disease mechanisms but also expanded the range of applications that benefit diverse patient populations.

In a world where medical precision and tailored therapies are becoming increasingly vital, plasma fractionation emerges as a cornerstone technology. Ongoing research, governmental policy support, and strategic industry collaborations further fuel the momentum behind this sector. The synthesis of cutting-edge technology with rigorous quality standards ensures a market that continues to evolve in both complexity and scope. As we delve into the nuances of this landscape, it becomes clear that success in this arena is built upon a solid foundation of scientific integrity, industry foresight, and relentless commitment to innovation.

Transformative Shifts in the Industry Landscape

The dynamics of the plasma fractionation landscape have experienced profound shifts marked by consolidation of research efforts, a surge in technological breakthroughs, and an ever-changing competitive environment. The advent of highly sophisticated bioprocessing techniques has revolutionized how plasma proteins are extracted and purified, ultimately enhancing the yield and purity of critical medicinal products. These advancements have translated into improved therapeutic efficacy and safety profiles, ushering in a new era of patient-centered healthcare.

In addition, strategic alliances and mergers between global stakeholders have altered the competitive framework, prompting companies to innovate at a pace that meets both regulatory mandates and market expectations. This transformation has led to an intensified focus on quality assurance, process optimization, and the rapid integration of next-generation technologies. Consequently, players in the plasma fractionation market are now compelled to not only maintain rigorous standards but also to anticipate and adapt to evolving clinical needs. The transition from traditional methods towards more automated, scalable, and sustainable practices symbolizes the metamorphosis of the industry and holds promise for future advancements.

Key Segmentation Insights Across Market Dimensions

An in-depth analysis of the plasma fractionation market reveals a comprehensive segmentation driven by multiple critical factors. When examined based on product type, the market consists of a vast array of therapeutic substances including Albumin, Coagulation Factor Concentrates, Immunoglobulins, and Protease Inhibitors. Further granularity in the Coagulation Factor Concentrates is achieved by dissecting the segment into essential components such as Factor VIII, Factor XIII, Fibrinogen Concentrates, and Prothrombin Complex Concentrate. The Immunoglobulins domain is also delineated into Intravenous Immunoglobulin and Subcutaneous Immunoglobulin, reflecting the tailored approach towards patient-specific treatments.

Market segmentation is also intricately mapped through the lens of the fractionation methods employed. These include Centrifugation, Cryoprecipitation, Ethanol Precipitation, Ion-Exchange Chromatography, and Ultrafiltration. This diversity in methodological approaches not only demonstrates the innovative capabilities of the industry but also underscores the importance of process-specific optimizations in achieving product excellence. The applications of these products further segment the market into important medical areas such as Hematology, Neurology, Oncology, and Rheumatology, emphasizing that treatment paradigms are increasingly specialized. Lastly, the end-user perspective divides the market into sectors involving Academic Institutions, Clinical Research Laboratories, and Hospitals & Clinics, each representing unique usage patterns and growth potential that collectively drive future strategies in the plasma fractionation market.

Based on Product Type, market is studied across Albumin, Coagulation Factor Concentrates, Immunoglobulins, and Protease Inhibitors. The Coagulation Factor Concentrates is further studied across Factor VIII, Factor XIII, Fibrinogen Concentrates, and Prothrombin Complex Concentrate. The Immunoglobulins is further studied across Intravenous Immunoglobulin and Subcutaneous Immunoglobulin.

Based on Method of Fractionation, market is studied across Centrifugation, Cryoprecipitation, Ethanol Precipitation, Ion-Exchange Chromatography, and Ultrafiltration.

Based on Application, market is studied across Hematology, Neurology, Oncology, and Rheumatology.

Based on End-User, market is studied across Academic Institutions, Clinical Research Laboratories, and Hospitals & Clinics.

Regional Dynamics and Growth Opportunities

The expansion of the plasma fractionation market is clearly visible when examined from a global perspective. Insights into regional markets bring forward a nuanced understanding of the dynamics at play. The Americas have set a robust precedent for market growth, largely driven by cutting-edge research facilities and stringent regulatory frameworks that ensure safety and innovation. This has paved the way for significant investment in infrastructure and technology across the region.

Moving to Europe, the Middle East and Africa, one finds a landscape characterized by progressive healthcare reforms and emerging technological adoption that are vital in bolstering market potential. The confluence of academic research and industrial application in these regions continues to nurture breakthroughs and strategic collaborations. Likewise, the Asia-Pacific region is experiencing remarkable growth fueled by expanding healthcare infrastructure, increasing awareness of advanced therapies, and a surge in clinical research initiatives. Collectively, these regions embody distinct opportunities and challenges, making it imperative for forward-thinking market participants to adapt their strategies and develop tailored solutions aimed at local market demands.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the Market

A cluster of pioneering companies plays a pivotal role in the evolution of the plasma fractionation market. Industry leaders such as 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., and Biotest AG by Grifols, S.A. have leveraged decades of expertise to continuously deliver innovative therapeutic solutions in plasma-based products. Their contributions set the benchmark in scientific research and process optimization.

Other notable players like China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., and GC Biopharma corp. are renowned for their advancements in manufacturing processes and rigorous adherence to quality standards that underpin successful market penetration. Additional organizations such as HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., and Kedrion S.p.A. further illustrate the significant momentum in the industry. Complementing these are firms including LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Shanghai Raas Blood Products Co. Ltd., SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd. Their unyielding focus on research and development, coupled with strategic investment in next-generation technologies, showcases a vibrant competitive landscape that is continuously adapting to meet the future demands of patient care.

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., GC Biopharma corp., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Shanghai Raas Blood Products Co. Ltd., SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.. Actionable Recommendations for Strategic Market Leaders

For industry leaders poised to capitalize on the emerging potential of the plasma fractionation market, a proactive and informed approach is essential. Decision-makers need to focus on integrating the latest technological advancements to enhance processing efficiency and accuracy. Embracing next-generation methodologies such as automated fractionation systems, machine learning tools for process optimization, and real-time quality control solutions can dramatically enhance operational capabilities.

It is advisable for executives to relentlessly invest in research and development programs that not only meet current market demands but also anticipate future shifts in the healthcare ecosystem. Emphasizing cross-collaboration with academic institutions and clinical research laboratories can lead to breakthrough innovations and refine the understanding of plasma-derived therapeutic products. Furthermore, market leaders should prioritize developing robust risk mitigation strategies that address regulatory challenges and compliance issues while keeping pace with the evolving industry standards. Strategic geographic expansion, particularly in high-growth regions with demonstrated potential, can provide a competitive advantage over rivals. Additionally, strengthening partnerships with key suppliers and logistics chains will ensure consistent quality and timely distribution of vital products, thereby cementing a reliable market presence. Finally, being agile and responsive to market fluctuations is imperative, as the pace of innovation in plasma fractionation necessitates continuous reassessment and realignment of business strategies.

Closing Thoughts and Market Outlook

In summary, the plasma fractionation market is navigating through a transformative phase marked by technological innovations, strategic mergers, and an expanding application base. The interplay of varied segmentation dimensions-from product type and fractionation methods to applications and end-user demographics-illustrates a complex yet promising market structure. The convergence of regional dynamism and the ever-growing emphasis on quality and efficiency is reshaping the industry's competitive fabric.

Future market trends indicate sustained growth that is propelled by continuous investments in technology, strategic innovations, and the evolving global demand for plasma-derived therapies. As companies realign their strategies to address both present and future challenges, the outlook remains robust and full of potential. This underscores the necessity for a deep understanding of the industry's segmentation, regional differences, and competitive dynamics, thereby enabling stakeholders to navigate the intricate landscape with confidence and precision.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising demand for plasma-derived therapies in treating immune and bleeding disorders
    • 5.1.1.2. Advancements in fractionation technologies enhancing yield and biosafety
    • 5.1.1.3. Expanding plasma collection networks and donor participation initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. High production costs and stringent regulatory compliance requirements
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing potential for plasma fractionation in emerging markets with increasing healthcare investments
    • 5.1.3.2. Development of recombinant alternatives and hybrid plasma-derived products for expanded applications
  • 5.1.4. Challenges
    • 5.1.4.1. Supply chain constraints and donor dependency impacting raw material availability
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Critical role of coagulation factor concentrates in managing bleeding disorders
  • 5.2.2. End-User: Pivotal role of academic institutions in advancing plasma fractionation research and education
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Plasma Fractionation Market, by Product Type

• 6.1. Introduction
• 6.2. Albumin
• 6.3. Coagulation Factor Concentrates
  • 6.3.1. Factor VIII
  • 6.3.2. Factor XIII
  • 6.3.3. Fibrinogen Concentrates
  • 6.3.4. Prothrombin Complex Concentrate
• 6.4. Immunoglobulins
  • 6.4.1. Intravenous Immunoglobulin
  • 6.4.2. Subcutaneous Immunoglobulin
• 6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Method of Fractionation

• 7.1. Introduction
• 7.2. Centrifugation
• 7.3. Cryoprecipitation
• 7.4. Ethanol Precipitation
• 7.5. Ion-Exchange Chromatography
• 7.6. Ultrafiltration

8. Plasma Fractionation Market, by Application

• 8.1. Introduction
• 8.2. Hematology
• 8.3. Neurology
• 8.4. Oncology
• 8.5. Rheumatology

9. Plasma Fractionation Market, by End-User

• 9.1. Introduction
• 9.2. Academic Institutions
• 9.3. Clinical Research Laboratories
• 9.4. Hospitals & Clinics

10. Americas Plasma Fractionation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Plasma Fractionation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Plasma Fractionation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. GC Biopharma advances its global market presence by integrating plasma fractionation supply chains through the strategic acquisition of ABO Holdings
  • 13.3.2. INA and SK Plasma join forces to launch Indonesia's first plasma fractionation facility, strengthening domestic supply chains
  • 13.3.3. SK Plasma secures investment from the Indonesia Investment Authority to develop a plasma fractionation plant in Karawang International Industrial City
  • 13.3.4. Takeda's US investment repurposes existing infrastructure to expand plasma-derived therapies capacity
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3M Company
• 2. ADMA Biologics, Inc.
• 3. Bharat Serums and Vaccines Limited
• 4. Bio Products Laboratory Ltd.
• 5. Biotest AG by Grifols, S.A.
• 6. China Biologic Products, Inc.
• 7. CSL Limited
• 8. Emergent BioSolutions Inc.
• 9. GC Biopharma corp.
• 10. HEINKEL Process Technology GmbH
• 11. Hemarus Therapeutics Ltd
• 12. Intas Pharmaceuticals Ltd.
• 13. Kamada Ltd.
• 14. Kedrion S.p.A.
• 15. LFB SA
• 16. Merck KGaA
• 17. Octapharma AG
• 18. PlasmaGen BioSciences Pvt. Ltd.
• 19. Prothya Biosolutions B.V.
• 20. Shanghai Raas Blood Products Co. Ltd.
• 21. SK Plasma Co.,Ltd.
• 22. STERIS plc
• 23. Takeda Pharmaceutical Company Ltd.